Lilly, with Alzheimer's in its crosshairs, forms new neuroscience unit, unifies oncology under Loxo exec

Neuroscience has zoomed up the agenda at Eli Lilly as the combination of data on donanemab and the accelerated approval of Biogen’s Aduhelm has opened up an opportunity in Alzheimer’s disease. Lilly has responded by splitting off its late-phase neurodegeneration and pain prospects into a new business unit.